Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vaccinex, Inc. VCNX
$0.41
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
19847610.00000000
-
week52high
1.50
-
week52low
0.34
-
Revenue
-175000
-
P/E TTM
-1
-
Beta
1.02731700
-
EPS
-0.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 25 сент 2020 г. |
| BTIG | Neutral | Buy | 23 сент 2020 г. |
| Oppenheimer | Outperform | 04 сент 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Frieberg Jacob B. | A | 19852 | 19852 | 31 дек 2022 г. |
| Zauderer Maurice | A | 181736 | 3988 | 06 дек 2022 г. |
| FRIEDBERG ALBERT | A | 15359011 | 3778575 | 23 ноя 2022 г. |
| Van Strydonck, Gerald E. | A | 67232 | 47232 | 23 ноя 2022 г. |
| Frieberg Jacob B. | A | 193049 | 188928 | 23 ноя 2022 г. |
| Zauderer Maurice | A | 4410984 | 1511430 | 23 ноя 2022 г. |
| Frieberg Jacob B. | A | 26260 | 26260 | 30 сент 2022 г. |
| Frieberg Jacob B. | A | 12064 | 12064 | 30 июн 2022 г. |
| Van Strydonck, Gerald E. | A | 53254 | 53254 | 12 мая 2022 г. |
| Stecyk Chrystyna Bedrij | A | 53254 | 53254 | 12 мая 2022 г. |
Новостная лента
Fcmi Parent Now Owns 42.8% of Vaccinex
24/7 Wall Street
06 апр 2023 г. в 22:23
Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
GlobeNewsWire
23 мар 2023 г. в 08:00
March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease
Should Investors Buy or Sell the Vaccinex Patent News?
MarketBeat
07 февр 2023 г. в 11:10
Shares of Vaccinex, Inc. (NASDAQ: VCNX) are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market trading on the news.
7 Penny Stocks To Watch With Big News In February; Time To Buy?
PennyStocks
07 февр 2023 г. в 09:12
Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?
Why Is Vaccinex (VCNX) Stock Up 67% Today?
InvestorPlace
07 февр 2023 г. в 07:41
Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today's gains come from increased interest from investors.